3524-34-3

Usage

Uses

Used in Pharmaceutical Synthesis:
5-METHYL-2-PROPYL-2H-PYRAZOL-3-YLAMINE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 5-METHYL-2-PROPYL-2H-PYRAZOL-3-YLAMINE serves as an intermediate, playing a crucial role in the creation of compounds that can be used in agricultural chemicals to protect crops and enhance yields.
Used in Research as a Reagent:
5-METHYL-2-PROPYL-2H-PYRAZOL-3-YLAMINE is utilized as a reagent in chemical reactions, particularly for the formation of new carbon-nitrogen bonds, which is essential for advancing the field of organic chemistry and material science.
Used in the Development of New Materials:
5-METHYL-2-PROPYL-2H-PYRAZOL-3-YLAMINE has shown potential as a building block for the development of new materials, indicating its versatility and importance in creating innovative compounds with biological activities and other applications.

InChI:InChI=1/C7H13N3/c1-3-4-10-7(8)5-6(2)9-10/h5H,3-4,8H2,1-2H3

Upstream product

• 2469-99-0 Cyanoaceton 
• 5039-61-2 n-propylhydrazine 
• 56795-66-5 propyl hydrazine hydrochloride 
• 1118-61-2 3-Aminocrotononitrile 

Downstream Products

• 89969-59-5 5-amino-4-<(2-bromo-5-nitrophenyl)azo>-3-methyl-1-propylpyrazole 
• 851520-86-0 4-chloro-3-methyl-1-propyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 
• 1027557-32-9 4-chloro-3-methyl-1-propyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 

Relevant academic research and scientific papers

Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M

The cullin-RING ubiquitin ligases (CRLs) are ubiquitin E3 enzymes that play a key role in controlling proteasomal degradation and are activated by neddylation. We previously reported inhibitors that target CRL activation by disrupting the interaction of defective in cullin neddylation 1 (DCN1), a CRL neddylation co-E3, and UBE2M, a neddylation E2. Our first-generation inhibitors possessed poor oral bioavailability and fairly rapid clearance that hindered the study of acute inhibition of DCN-controlled CRL activity in vivo. Herein, we report studies to improve the pharmacokinetic performance of the pyrazolo-pyridone inhibitors. The current best inhibitor, 40, inhibits the interaction of DCN1 and UBE2M, blocks NEDD8 transfer in biochemical assays, thermally stabilizes cellular DCN1, and inhibits anchorage-independent growth in a DCN1 amplified squamous cell carcinoma cell line. Additionally, we demonstrate that a single oral 50 mg/kg dose sustains plasma exposures above the biochemical IC90 for 24 h in mice.

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

JTE013 ANALOGS AND METHODS OF MAKING AND USING SAME

JTE013 analogs having similar or greater stability relative to JTE013 are provided. Also provided are JTE013 analogs which can bind to both S1P2 and S IP5, some of which also have similar or greater stability relative to JTE013. In a

The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist

The identification of novel, potent, non-steroidal/small molecule functional GR antagonist GSK1564023A selective over PR is described. Associated structure-activity relationships and the process of optimisation of an initial HTS hit are also described.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

(1,3-Dialkyl-5-amino-1H-pyrazol-4-yl)arylmethanones. A series of novel central nervous system depressants

A series of novel (1,3-dialkyl-5-amino-1H-pyrazol-4-yl)arylmethanones was synthesized. Pharmacological evaluation of these compounds demonstrated central nervous system depressant activity, potential anticonvulsant properties, and a low order of acute toxicity. In addition, selected compounds showed potential antipsychotic effects. This report focuses on the synthesis and structure-activity relationships of these compounds. (5-Amino-1-ethyl-3-methyl-1H-pyrazol-4-yl)(2-chlorophenyl)methanone was the most active compound against pentylene-tetrazole-induced convulsions. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(3-chlorophenyl)methanone also has a favorable anticonvulsant depression ratio. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(3-trifluoromethylphenyl)methanone, (5-amino-1,3-dimethyl-1H-pyrazol-4-yl)(3-thienyl)methanone and (5-amino-3-ethyl-1-methyl-1H-pyrazol-4-yl)phenylmethanone are very potent depressants. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-thienyl)methanone possessed marked central depressant activity without anticonvulsant activity and without impairment of motor functioning. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanone has a behavioral profile suggestive of antipsychotic activity and gave a positive Ames test result.